linjc16/ctgov huggingface dataset:
Pharmacogenetic Study of Methylphenidate in Attention Deficit/Hyperactivity Disorder(ADHD)

Study Overview
=================
Brief Summary
-----------------
The noradrenergic system plays a known role in attentional systems and suspected causal role in attention deficit/hyperactivity disorder(ADHD).Methylphenidate also has been suspected as a inhibitor of norepinephrine transporter(SLC6A2). The investigators hypothesis is that norepinephrine transporter polymorphism is associated with responses and adverse effects of OROS-methylphenidate in treatment of ADHD.

Official Title
-----------------
Association Between Norepinephrine Transporter Polymorphism and Response of Methylphenidate

Conditions
-----------------
Attention Deficit Disorder With Hyperactivity, Methylphenidate, Pharmacogenetics

Intervention / Treatment
-----------------
* Genetic: norepinephrine transporter polymorphism,


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ADHD Physically healthy Exclusion Criteria: Neurological illness Concurrent additional psychiatric treatment < IQ 70 Psychotic disorder Major mood disorder needed other psychiatric medication Significant suicidal ideation Pervasive developmental disorder

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: open label<br> | Genetic: norepinephrine transporter polymorphism,<br>* OROS methylphenidate (Concerta) monopharmacotherapy dose : 18-54mg duration : 8 weeks genotyping : norepinephrine transporter (SLC6A2) polymorphism<br>* Other names: genotyping : norepinephrine transporter (SLC6A2) polymorphism;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Korean ADHD Rating scale-parent version (KARS) |  | baseline,1,2,4,8 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Barkely side effect rating scale |  | 1,2,4,8weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ADHD,, norepinephrine transporter, pharmacogenetics
Use of Analgesic Drugs in Renal Colic in Emergency Room

Study Overview
=================
Brief Summary
-----------------
A prospective non-interventional study on the use of analgesic drugs in renal colic in emergency rooms

Official Title
-----------------
Use of Analgesic Drugs in Renal Colic in Emergency Room

Conditions
-----------------
Renal Colic

Intervention / Treatment
-----------------
* Other: Consumption of drugs for analgesic use


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients older than 18 years old Suspicion of renal colic (pain in a lumbar pit radiating to the external genital organs, rapidly progressive onset, non-febrile) Exclusion Criteria: Shock Glasgow score less than 15 Oxygen saturation less than 93% in ambient air Signs of intracranial hypertension (headache associated with vomiting) Suspicion of pneumothorax History of emphysema or chronic obstructive pulmonary disease Diving accident or suspicion of gas embolism Trauma of the face of interest in the area of application of the mask Abdominal gas distension Contraindication in Nonsteroidal anti-inflammatory drugs Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patient with renal colic<br> | Other: Consumption of drugs for analgesic use<br>* Regular assessment of pain Drug data will be collected (name, dosage, route of administration, time of delivery)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of analgesic drug used in the context of renal colic in emergency rooms by following the recommended and validated service protocol | Collection of name, dosage, route of administration, time of issue of the drug | During hospitalisation in emergency rooms |
Ultrasound and X-ray in Detecting Articular Cartilage Calcification

Study Overview
=================
Brief Summary
-----------------
Prospective study with an echography of the 2 knees and radiography of the 2 knees (front and profile) for each patient. If found calcification on ultrasound further examination with ultrasound wrists, hips and shoulders.

Detailed Description
-----------------
Osteo-articular echography is currently recognized as an important development among rheumatologists. Chondrocalcinosis, which can promote joint inflammation and cartilage degeneration, is highly prevalent in elderly subjects. Osteo-articular echography is currently reconized as an important development among rheumatologists and can efficiently use to detect Chondrocalcinosis. The aim of this study is to find a correlation between radiography and echography in detecting CPPD crystal deposition, on a sample of patients and more important with a new generation of ultrasound with a probe superficial performance. 166 patients will be enrolled in this trial and an echography and a radiography of the 2 knees (front and profile) will be done for each patient. Ih the echography show a calcification, further exams with wrists, hips shoulders echographies will be conducted. In case of liquid epanchement, analysis of the liquid will be carried in order to eliminate the differential diagnostic including septic arthritis

Official Title
-----------------
Concordance Entre l'échographie du Genou et la Radiographie Standard Dans la détection Des Calcifications Dans le Cadre de la Chondrocalcinose Articulaire

Conditions
-----------------
Chondrocalcinosis, Articular Cartilage Calcification

Intervention / Treatment
-----------------
* Procedure: Echography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patient> 70 years articular pathology of the knee consent signed Exclusion Criteria: Not covered by social security

Ages Eligible for Study
-----------------
Minimum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Echography|Echography|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Knee calcification detected by echography and radiography |  | Day 1 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Calcification description and other localisations finding |  | Day 1 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Inflammation of bone and cartilage
Coronary CT Angiography Using 320-Row Volume CT in Patients With Atrial Fibrillation

Study Overview
=================
Brief Summary
-----------------
The primary objective of this study is to analyze the diagnostic accuracy of coronary CT angiography using 320 simultaneous detector results in patients with atrial fibrillation.

Official Title
-----------------
Coronary CT Angiography Using 320-Row Volume CT in Patients With Atrial Fibrillation

Conditions
-----------------
Atrial Fibrillation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Suspected coronary artery disease based on clinical findings or findings on other noninvasive imaging tests and planned coronary angiography within the next 14 days. Able to understand and willing to sign the Informed CF. Exclusion Criteria: Creatinine of above 2.0 mg/dl Age below 50 years Women of child bearing potential (no hysterectomy, no menopause, or menopause since less than 12 months) must demonstrate a negative pregnancy test performed within 24 hours before CT. Inability to hold the breath for 10 seconds

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Atrial Fibrillation<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Patients with atrial fibrillation
Femoral Neck System and Multiple Cannulated Screws in Femoral Neck Fracture

Study Overview
=================
Brief Summary
-----------------
Investigators will compare the clinical outcomes of femoral neck system with conventional multiple cannulated screw in non-displaced femoral neck fracture.

Detailed Description
-----------------
Clinical outcomes include reoperation, loss of fixation, and change of mobility.

Official Title
-----------------
Comparison Between Femoral Neck System and Multiple Cannulated Screws in Non-displaced Femoral Neck Fracture

Conditions
-----------------
Femoral Neck Fractures

Intervention / Treatment
-----------------
* Device: Femoral Neck System
* Device: Multiple Cannulated Screw


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years and older non-displaced femoral neck fracture community ambulator Exclusion Criteria: younger than 18 years displaced femoral neck fracture intertrochanteric fracture subtrochanteric fracture

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: FNS<br>those who are treated with femoral neck system (FNS) | Device: Femoral Neck System<br>* femoral neck system using bolt and antirotation screw with one/two hole plate<br>|
| Active Comparator: MCS<br>those who are treated with multiple cannulated screw (MCS) | Device: Multiple Cannulated Screw<br>* multiple cannulated screw using 3 or 4 cannulated screw<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reoperation | rate of reoperation | 3 months | 
| Reoperation | rate of reoperation | 6 months | 
| Reoperation | rate of reoperation | 9 months | 
| Reoperation | rate of reoperation | 12 months | 
| Reoperation | rate of reoperation | 24 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| loss of fixation | Rate of loss of fixation | 3 months | 
| loss of fixation | Rate of loss of fixation | 6 months | 
| loss of fixation | Rate of loss of fixation | 9 months | 
| loss of fixation | Rate of loss of fixation | 12 months | 
| loss of fixation | Rate of loss of fixation | 24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Femoral Neck Fractures
Calmodulin Gene Mutations in Patients With Ventricular Arrhythmia of Unknown Origin - A Screening Study

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to screen a well characterized patient population with ventricular tachycardia of unknown origin and treated with an implantable cardioverter-defibrillator (ICD) for mutations in the calmodulin genes.

Detailed Description
-----------------
Patients with ventricular tachycardia of unknown origin and treated with an implantable cardioverter-defibrillator (ICD) will be asked to participate in the study. For patients with results showing mutations in the calmodulin genes, family members (parents, siblings and children) will also be asked to participate in the study. For under age patients and relatives who agree to participate, informed consent will also be taken from their custodian.

Official Title
-----------------
Calmodulin Gene Mutations in Patients With Ventricular Arrhythmia of Unknown Origin - A Screening Study

Conditions
-----------------
Ventricular Tachycardia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with ventricular tachycardia of unknown origin that have been treated with an ICD Signed and dated informed consent Exclusion Criteria: - Inability to provide informed consent
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Ventricular tachycardia<br>Patients with ventricular tachycardia of unknown origin treated with an ICD. | |
| Family members<br>Family members (parents, siblings and children) for patients with results showing mutations in the calmodulin genes. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mutations in the calmodulin genes |  | 1 month. |
Transbronchial Needle Aspiration in the Diagnosis of Peripheral Pulmonary Malignancy

Study Overview
=================
Brief Summary
-----------------
The main purposes of this study are to assess the performance characteristics of transbronchial needle aspiration (TBNA) in the diagnosis of peripheral pulmonary lesions, and to identify the predictor variables of a positive aspirate.

Detailed Description
-----------------
In a recent systematic literature review (Rivera PM, Mehta AC; Chest 2007; 132: 1318-1488) TBNA showed the highest sensitivity in the diagnostic bronchoscopic approach to peripheral pulmonary lesions, as compared to the other available sampling techniques (transbronchial biopsy, brushing, washings). However, the Authors conclude that the data regarding TBNA in this setting deserve cautious interpretation because of the limited number of studies and the large differences in sample size). We designed the present study to assess the performance characteristics of TBNA, alone and in comparison with those of transbronchial biopsy, in the diagnosis of peripheral pulmonary lesions.

Official Title
-----------------
Transbronchial Needle Aspiration in the Diagnosis of Peripheral Pulmonary Malignancy: Yield and Predictors of a Positive Aspirate

Conditions
-----------------
Pulmonary Nodule, Pulmonary Mass

Intervention / Treatment
-----------------
* Procedure: TBNA + transbronchial lung biopsy + bronchial washing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 years and older Pulmonary nodule (< 3 cm) or mass (> 3 cm) at computed tomography Exclusion Criteria: Refusal to sign informed consent Uncontrolled coagulopathy Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 76 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Peripheral pulmonary lesions<br> | Procedure: TBNA + transbronchial lung biopsy + bronchial washing<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assess sensitivity, specificity and accuracy of TBNA in the diagnosis of peripheral pulmonary lesions |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluate the predictor variables associated with a positive TBNA result |  | 1 year | 
| Compare the performance characteristics of TBNA and transbronchial lung biopsy |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Lung cancer, Lung nodule, Transbronchial needle aspiration, Transbronchial lung biopsy, Bronchoscopy
Perioperative Respiratory Adverse events_sugammadex

Study Overview
=================
Brief Summary
-----------------
Perioperative respiratory adverse events are common in children. We aimed to evaluate the effect of sugammadex on the incidence of perioperative respiratory adverse events in pediatric patients receiving tonsillectomy

Official Title
-----------------
Effect of Sugammadex Versus Neostigmine on the Occurrence of Respiratory Adverse Events in Children Undergoing Tonsillectomies: a Randomized Controlled Trial

Conditions
-----------------
Respiratory Complication

Intervention / Treatment
-----------------
* Drug: Sugammadex injection
* Drug: Neostigmine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pediatric patients aged 2-6 years who were scheduled for tonsillectomy under general anesthesia were enrolled Exclusion Criteria: a recent history of upper respiratory tract infection within 2 weeks of surgery allergic reaction to sugammadex renal failure liver failure arrhythmia

Ages Eligible for Study
-----------------
Minimum Age: 2 Years
Maximum Age: 6 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Sugammadex as reversal agent<br> | Drug: Sugammadex injection<br>* sugammadex as reversal agent<br>|
| Active Comparator: Neostigmine as reversal agent<br> | Drug: Neostigmine<br>* neostigmine as a reversal agent<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Perioperative respiratory adverse events | the incidence of overall perioperative respiratory adverse events; oxygen desaturation < 95%, airway obstruction, laryngospasm, bronchospasm, severe coughing, or postoperative stridor | from induction of anesthesia to end of operation, about 3 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| bradycardia | administration of IV atropine, glycopyrrolate, epinephrine, ephedrine | from induction of anesthesia to end of operation, about 3 hours | 
| Cardiac arrest | documented chest compressions/defibrillation/cardioversion | from induction of anesthesia to end of operation, about 3 hours | 
| Anaphylaxis | administration of epinephrine, methylprednisolone, diphenhydramine, documented diagnosis of anaphylactic/ anaphylatoid reaction | from induction of anesthesia to end of operation, about 3 hours | 
| Allergic reaction | redness, urticaria, wheeze | from induction of anesthesia to end of operation, about 3 hours | 
| Bronchospasm | administration of albuterol, epinephrine | from induction of anesthesia to end of operation, about 3 hours | 
| Nausea and vomiting |  | from induction of anesthesia to end of operation, about 3 hours |
Prognostic Value of Rb-82 PET Myocardial Perfusion Imaging

Study Overview
=================
Brief Summary
-----------------
The physician would like to see if nuclear cardiac stress tests can predict cardiac health. For example, if a patient has an abnormal stress test, is he or she more likely to have cardiac problems in the future?

Conditions
-----------------
Cardiac Health

Intervention / Treatment
-----------------
* Other: questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient > or = to 18 years of age Registered patient at MSKCC Patient with one or more 82Rb myocardial perfusion stress tests performed at MSKCC, 2008-2011 Exclusion Criteria: Patient is unwilling to participate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| pts who have had Rb-82 PET myocardial perfusion imaging<br>Eligible patients will have had Rb-82 PET myocardial perfusion imaging at MSKCC, 2008 - 2011. Patients will complete one questionnaire over the phone. | Other: questionnaire<br>* Patients will complete one questionnaire over the phone. We will ask patients to describe their cardiac history since Rb-82 PET (chest pain, shortness of breath, cardiac catheterization, and heart attack). This information will be correlated to the scan results and other relevant information in the patient's medical record.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| correlate scan findings with clinical outcomes | Patients will complete one questionnaire over the phone. | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
stress test, cardiac issues, Rb-82 PET Myocardial Perfusion Imaging, 11-150, one or more 82Rb myocardial perfusion stress tests
Bilateral Laryngeal Paralysis Reinnervation

Study Overview
=================
Brief Summary
-----------------
Bilateral laryngeal reinnervation induces a rise in laryngeal resistance and speech alteration. The aim of this study is to propose laryngeal reinnervation by a phrenic nerve root to patients with bilateral laryngeal paralysis.

Official Title
-----------------
Bilateral Laryngeal Paralysis Reinnervation. Speech and Ventilatory Results Analysis

Conditions
-----------------
Vocal Cord Paralysis

Intervention / Treatment
-----------------
* Procedure: surgical reinnervation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Bilateral laryngeal paralysis without any amelioration for six months Exclusion Criteria: Laryngeal paralysis more than 3 years Arycricoideus ankylostosis Pacemaker Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: surgical reinnervation|laryngeal reinnervation with a phrenic nerve root|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| LARYNGEAL REINNERVATION |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
bilateral vocal cord paralysis, reinnervation, phrenic nerve